X-ray crystal structure of SANGIVAMYCIN (cas 18417-89-5), a potent inhibitor of protein kinases
-
Add time:09/02/2019 Source:sciencedirect.com
The X-ray crystal structure of sangivamycin, a potent nucleoside inhibitor of protein kinases, has been determined. Sangivamycin crystallizes from water with its purine ring in a conformation anti to its ribose sugar. Such an anti conformation has been detected in solution for sangivamycin and other potent protein kinase inhibitors and appears to correlate with inhibitor potency [(1990) Biochemistry (in press)]. An intramolecular hydrogen bond between purine ring substituents is detected in the X-ray structure and may be an important structural feature of sangivamycin related to its degree of inhibition of rhodopsin kinase and of protein kinases C and A.
We also recommend Trading Suppliers and Manufacturers of SANGIVAMYCIN (cas 18417-89-5). Pls Click Website Link as below: cas 18417-89-5 suppliers
Prev:Synthesis of 2′-β-C-methyl toyocamycin and SANGIVAMYCIN (cas 18417-89-5) analogues as potential HCV inhibitors
Next:In vivo and enzymatic conversion of toyocamycin to SANGIVAMYCIN (cas 18417-89-5) by Streptomyces rimosus☆) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Antiviral activities of 2′-deoxyribofuranosyl and arabinofuranosyl analogs of SANGIVAMYCIN (cas 18417-89-5) against retro- and DNA viruses09/07/2019
- Effect of SANGIVAMYCIN (cas 18417-89-5) and xylosyladenine on the synthesis and methylation of polysomal ribonucleic acid in Ehrlich ascites cells in vitro09/06/2019
- Comparison between the inhibitory activities of SANGIVAMYCIN (cas 18417-89-5) and thioSANGIVAMYCIN (cas 18417-89-5) on nuclear ribonucleic acid synthesis in L1210 cells in vitro09/05/2019
- Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin, SANGIVAMYCIN (cas 18417-89-5) and thioSANGIVAMYCIN (cas 18417-89-5)☆09/04/2019
- In vivo and enzymatic conversion of toyocamycin to SANGIVAMYCIN (cas 18417-89-5) by Streptomyces rimosus☆09/03/2019
- Synthesis of 2′-β-C-methyl toyocamycin and SANGIVAMYCIN (cas 18417-89-5) analogues as potential HCV inhibitors09/01/2019
- ArticleDeciphering Deazapurine Biosynthesis: Pathway for Pyrrolopyrimidine Nucleosides Toyocamycin and SANGIVAMYCIN (cas 18417-89-5)08/31/2019
- SANGIVAMYCIN (cas 18417-89-5) induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells08/30/2019


